Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.86 |
| ▸ | CD44 | P16070 | 2/20 | 0.86 |
| ▸ | MAOB | P27338 | 1/20 | 0.86 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL19085 | 0.93 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.93 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28236302 | 0.93 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5411332 | 0.91 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL11838922 | 0.91 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11213530 | 0.91 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL11457582 | 0.91 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL2082936 | 0.91 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL20524019 | 0.91 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6635293 | 0.91 | PNMT (0.95) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105263490-B | Substituted triazolopyridines and methods of use | 基因泰克公司 | 2018-05-22 | — | — | CN | disclosed |
| US-9550775-B2 | Substituted triazolopyridines and methods of use thereof | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2968280-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105263490-A | Substituted triazolopyridines and methods of use | GENENTECH INC | 2016-01-20 | — | — | CN | disclosed |
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2016-01-14 | — | — | US | disclosed |
| WO-2014153037-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009710-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF | P2RX3, P2RX1, P2RX4 | PNMT 2136/4885CD44 4840/4885MAOB 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.